(Reuters) - NEW YORK, July 24 - Wyeth on Tuesday said U.S. regulators are unwilling to approve its experimental drug Pristiq for hot flashes until the company resolves concerns about its potential to cause serious heart and liver problems.
Wyeth said the FDA has requested a new trial for the drug that could take a year or longer to complete, in order to better demonstrate the drug's safety in post-menopausal women.
Read more at Reuters.com Market News
Wyeth said the FDA has requested a new trial for the drug that could take a year or longer to complete, in order to better demonstrate the drug's safety in post-menopausal women.
Read more at Reuters.com Market News
No comments:
Post a Comment